A sterile injectable CDMO from clinical to commercial is a partner that can take your product all the way from its first Phase I batches to full commercial supply, without forcing a change of site along the way. That journey involves clinical trial material, technology transfer, Chemistry, Manufacturing and Controls (CMC) documentation for regulatory submissions, and a careful scale-up that keeps quality steady as volumes grow. This guide sets out what happens at each stage, and how an integrated partner keeps the path smooth.
Table of contents
- What does moving a sterile injectable from clinical to commercial involve?
- Clinical supply: from feasibility to Phase III batches
- Technology transfer between stages
- CMC documentation for EMA and FDA submissions
- Scaling up from clinical batches to commercial volumes
- Why an integrated CDMO network reduces risk
- How Adragos supports the journey from clinical to commercial
- Frequently asked questions
What does moving a sterile injectable from clinical to commercial involve?
Moving a sterile injectable from clinical to commercial supply is a staged journey, and the risk usually sits in the handovers between stages rather than in any single step. A complete path covers four things:
- Clinical supply, from feasibility work through to Phase III batches.
- Technology transfer that carries the process cleanly between stages.
- CMC documentation that supports European Medicines Agency and United States Food and Drug Administration submissions.
- Scale-up that grows batch sizes while holding quality steady.
The fewer times a product changes hands or changes site, the lower the risk of delay. That is why the choice of partner matters as much as the choice of process.
Clinical supply: from feasibility to Phase III batches
Early clinical supply is where a programme finds out whether a process is ready. A capable partner supports the full range of clinical trial material, from feasibility assessment and toxicology study material through to stability samples, pilot batches and Good Manufacturing Practice (GMP) clinical manufacturing. At our Jura site in Switzerland we guide projects through each of these phases, with process alignment to GMP built in, so the move to the next stage is a step forward rather than a restart.
Technology transfer between stages
Technology transfer is the hinge of the whole journey. Every time a process moves, from development into clinical, or from clinical into commercial, the details of the method, the equipment and the controls have to move with it. A structured transfer, with clear documentation and a single point of contact, is what keeps a product on track. When the receiving site sits inside the same network as the sending site, that transfer is far simpler, because the quality systems and the people already speak the same language.
CMC documentation for EMA and FDA submissions
Commercial supply is only possible once the regulators are satisfied, and that rests on the CMC documentation. A strong partner provides a complete technology transfer package, process validation data and ongoing stability studies, and can compile the file in electronic Common Technical Document (eCTD) format for European Medicines Agency and United States Food and Drug Administration submissions. You can review the current expectations on the European Medicines Agency good manufacturing practice pages and in the United States Food and Drug Administration guidance on sterile drug products produced by aseptic processing. Submission-ready documentation is what turns a validated process into approved commercial supply.
Scaling up from clinical batches to commercial volumes
Scale-up is where many programmes feel the strain, because a process that works at clinical scale has to hold quality as volumes rise. The right partner lets you grow without a change of site. At our Jura site we apply no minimum batch size and can fill up to 74,400 vials, which suits products moving from clinical trial materials into small and medium commercial supply. For larger commercial volumes, our Maisons-Alfort site produces more than 130 million units per year, with high-speed prefilled syringe filling and large-scale freeze-drying of up to 70,000 vials. That range means a product can scale within the same network rather than searching for a new home at each step.
Why an integrated CDMO network reduces risk
An integrated network reduces risk because it removes handovers. Instead of transferring a product between unrelated companies as it grows, you keep it inside one quality system, with one set of standards and one team that knows the programme. This matters most for sterile injectables, where every transfer is a fresh contamination and validation risk. Before you commit to a partner, it is worth knowing exactly what to look for, and our guide on how to audit a sterile injectable CDMO sets out the full checklist.
How Adragos works as a sterile injectable CDMO from clinical to commercial
We support sterile injectable programmes across four European sites, so a product can be matched to the right stage and format within a single network:
- Jura, Switzerland: clinical trial material and small to medium commercial supply, with aseptic fill-finish of liquid and lyophilised vials and no minimum batch size.
- Maisons-Alfort, France: commercial-scale prefilled syringes and liquid and lyophilised vials, with high-speed aseptic filling and large-scale freeze-drying.
- Livron, France: ampoules with aseptic and terminal sterilisation, plus suppositories.
- Halden, Norway: sterile liquids in intravenous bags and ampoules produced with Blow-Fill-Seal technology.
Because these sites share one quality culture, a product can start clinical at one site and scale commercial at another without leaving the network. To map out a specific path from clinical to commercial, contact our sterile injectable team.
Frequently asked questions
What is clinical trial material?
Clinical trial material is the product manufactured under Good Manufacturing Practice for use in clinical studies. For sterile injectables it includes toxicology study material, stability samples and pilot batches, produced before a process is scaled for commercial supply.
Why does technology transfer matter when scaling a sterile injectable?
Technology transfer carries the method, equipment settings and controls from one stage or site to the next. A structured transfer keeps quality consistent and avoids repeating work, which protects both the timeline and the product.
Can one CDMO handle both clinical and commercial sterile supply?
Yes. A partner with an integrated network can support clinical trial material and commercial supply within the same quality system, which removes handovers between unrelated companies and lowers risk as the product scales.
What documentation is needed to move from clinical to commercial supply?
Commercial supply requires a complete technology transfer package, process validation data and ongoing stability studies, compiled for European Medicines Agency and United States Food and Drug Administration submissions in electronic Common Technical Document format.
